Back to results
US 2019/0290656 A1Published application
Pt(iv) prodrugs
AssigneeYissum Research Development Company of the Hebrew University of Jerusalem
InventorDan Gibson
Life of this patent
Estimating the term…
Abstract
The invention provides a novel class of Pt-based anticancer compounds exhibiting multiple anticancer activity.
Claims25
A compound comprising a platinum atom associated to one or more phenyl butyrate ligand, the compound optionally comprising one or more therapeutically active anticancer moiety.
(canceled)
(canceled)
(canceled)
-30. (canceled)
(canceled)
(canceled)
-51. (canceled)
-57. (canceled)
A compound selected from:
- wherein L is a therapeutically active anticancer moiety selected from the group consisting of pyruvate dehydrogenase kinase (PDK) inhibitors, histone deacetylase (HDAC) inhibitors, DNA methylation enhancers, COX inhibitors, PARP inhibitors, DNA repair inhibitors and cancer targeting moieties,
- wherein each of the therapeutically active anticancer moiety may be bonded via a —O—C(═O)— group.
-62. (canceled)
(canceled)
Dependencies are inferred from the claim text.